Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
The New England Journal of Medicine
|
February 18, 2026
Revival of Ethionamide by Alpibectir
Michel Pieren, Glenn E Dale, Marc Gitzinger, et al.
Life Sciences
|
January 21, 2024
Vaporized Δ9-THC in utero results in reduced birthweight, increased locomotion, and altered wake-cycle activity dependent on dose, sex, and diet in the offspring
Nicole M Roeder, Samantha L Penman, Brittany J Richardson, et al.
Toxicology and Applied Pharmacology
|
July 31, 2020
The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine
Carol E Jolly, Oisin Douglas, Laleh Kamalian, et al.
Pharmacology, Biochemistry, and Behavior
|
September 16, 2023
FABP5 is important for cognitive function and is an important regulator of the physiological effects and pharmacokinetics of acute Δ9 tetrahydrocannabinol inhalation in mice
Samantha L Penman, Nicole M Roeder, Erin C Berthold, et al.
British Journal of Pharmacology
|
July 19, 2020
Safety perspectives on presently considered drugs for the treatment of COVID-19
Sophie L Penman, Robyn T Kiy, Rebecca L Jensen, et al.
Journal of Clinical Pharmacology
|
March 7, 2026
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Laura Iavarone, Silvia M Lavezzi, Antonio J Carcas, et al.
The Journal of Antimicrobial Chemotherapy
|
April 24, 2024
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug
Michel Pieren, Ana Abáigar Gutiérrez-Solana, Rosa María Antonijoan Arbós, et al.
Nature Medicine
|
February 16, 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
Andreas H Diacon, Clifton E Barry, Alex Carlton, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
The New England Journal of Medicine
|
February 18, 2026
Revival of Ethionamide by Alpibectir
Michel Pieren, Glenn E Dale, Marc Gitzinger, et al.
Life Sciences
|
January 21, 2024
Vaporized Δ9-THC in utero results in reduced birthweight, increased locomotion, and altered wake-cycle activity dependent on dose, sex, and diet in the offspring
Nicole M Roeder, Samantha L Penman, Brittany J Richardson, et al.
Toxicology and Applied Pharmacology
|
July 31, 2020
The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine
Carol E Jolly, Oisin Douglas, Laleh Kamalian, et al.
Pharmacology, Biochemistry, and Behavior
|
September 16, 2023
FABP5 is important for cognitive function and is an important regulator of the physiological effects and pharmacokinetics of acute Δ9 tetrahydrocannabinol inhalation in mice
Samantha L Penman, Nicole M Roeder, Erin C Berthold, et al.
British Journal of Pharmacology
|
July 19, 2020
Safety perspectives on presently considered drugs for the treatment of COVID-19
Sophie L Penman, Robyn T Kiy, Rebecca L Jensen, et al.
Journal of Clinical Pharmacology
|
March 7, 2026
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Laura Iavarone, Silvia M Lavezzi, Antonio J Carcas, et al.
The Journal of Antimicrobial Chemotherapy
|
April 24, 2024
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug
Michel Pieren, Ana Abáigar Gutiérrez-Solana, Rosa María Antonijoan Arbós, et al.
Nature Medicine
|
February 16, 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
Andreas H Diacon, Clifton E Barry, Alex Carlton, et al.
Page
of 3